Linden has over 12 years of experience in medical and biotechnology investing, including 5 years as an equity analyst at Goldman Sachs, before moving to the buy side where she worked as a pharmaceutical and technology analyst at the hedge fund Clear River Capital and finally to her current role at AXA. Linden is a CFA Charterholder and has a Bachelor’s degree in Medical Microbiology.
AXA Investment Managers is one of the largest global asset managers, with assets under management of €746 billion (as of December 2017). It was founded in 1994 and has run a full range of products since, and is wholly owned and supported by the AXA Group. The group manages a full spectrum of products including equities, fixed income, alternatives and property.